Grupo Protege

Endpoint Security Global Market Report 2022: Featuring VMware, McAfee, Palo Alto Networks, Sophos, CrowdStrike & More - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023
Technology, Security, Benchmark, Agriculture, Software, Coronavirus, Government, Economic Times, Telecommunication, Smartphone, GDP, Personal computer, Vertical, Growth, The Economic Times, Grupo Protege, Scan, Financial services, Machine learning, DNS, BFSI, Health care, Create, E-commerce, Marketing, Video game, Defense, Insurance

The "Endpoint Security Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endpoint Security Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in this end-point security market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
  • The increasing number of end-points is expected to propel the growth of the end-point security market going forward.
  • Major companies operating in the market are introducing disruptive technologies to sustain their position in the end-point security market.

Endpoint Security Global Market Report 2022: Sector to Reach $22 Billion by 2026 at a CAGR of 9.4%

Retrieved on: 
Tuesday, January 3, 2023
Benchmark, Health care, Financial services, DNS, GDP, Telecommunication, E-commerce, Smartphone, Personal computer, Government, Growth, Economic Times, The Economic Times, BFSI, Coronavirus, Vertical, Agriculture, Scan, Software, Create, Machine learning, Grupo Protege, Renewable energy, Marketing, Video game, Defense, Insurance

DUBLIN, Jan. 3, 2023 /PRNewswire/ -- The "Endpoint Security Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 3, 2023 /PRNewswire/ -- The "Endpoint Security Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in this end-point security market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
  • The increasing number of end-points is expected to propel the growth of the end-point security market going forward.
  • Major companies operating in the market are introducing disruptive technologies to sustain their position in the end-point security market.

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil

Retrieved on: 
Tuesday, November 30, 2021
GMP, Patient, Man, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prostate cancer, Prostate, Radiopharmaceutical, CEO, Brazilian Health Regulatory Agency, Lung cancer, Company, ASX, Injection, Cancer, Male, TGA, MTR, RPH, Physician, Gallium, GLOBE, PET, Innovation, PSMA, FDA, Kit, TLX, Australian Securities Exchange, Nuclear medicine, Grupo Protege, LinkedIn, Disease, Degenerative disease, Food, Medical imaging

Illuccix (Kit for the preparation of 68Ga PSMA-11 Injection) is a positron emission tomography (PET) imaging agent targeting prostate specific membrane antigen (PSMA) for the staging of prostate cancer.

Key Points: 
  • Illuccix (Kit for the preparation of 68Ga PSMA-11 Injection) is a positron emission tomography (PET) imaging agent targeting prostate specific membrane antigen (PSMA) for the staging of prostate cancer.
  • Dr. Christian Behrenbruch, CEO and Managing Director of Telix said, Prostate cancer is the most commonly diagnosed male cancer in Brazil, with approximately 65,840 new cases each year.2 PSMA-PET imaging has the potential to have a profound impact on the management of prostate cancer, enabling clinicians to detect prostate cancer right throughout the body.
  • We look forward to working closely with our partner RPH to facilitate widespread patient access to Illuccix for men living with prostate cancer in Brazil.
  • Illuccix (TLX591-CDx) is a preparation for imaging prostate cancer with positron emission tomography (PET), targeting prostate specific membrane antigen (PSMA), a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells.